News

What to Expect from Neurocrine Biosciences's Earnings
Return on Assets (ROA): Neurocrine Biosciences's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 2.84%, the company showcases ...
The Manila Times2d
Nxera Pharma Operational Highlights and Consolidated Results for the First Quarter 2025
Tokyo, Japan and Cambridge, UK, 2 May 2025 - Nxera Pharma ("the Company” or "Nxera”; TSE: 4565) provides an update on ...
Neurocrine begins Phase III programme for schizophrenia treatment
The primary goal of the trial is to measure the decrease in the Positive and Negative Syndrome Scale from baseline.
Barron's4d
Harmony Biosciences Holdings Inc.
About Harmony Biosciences Holdings Inc. Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical company, which engages in the provision of development and commercialization of ...
TipRanks on MSN4d
Nxera Pharma’s Schizophrenia Treatment Enters Phase 3 Trials
An update from Sosei Group ( ($JP:4565) ) is now available. Nxera Pharma announced that its partner, Neurocrine Biosciences, has initiated a Phase ...
Neurocrine Biosciences Initiates Phase 3 Registrational Program for NBI-1117568 as Potential Treatment for Adults with Schizophrenia
Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the initiation of a Phase 3 registrational program to evaluate the efficacy, safety and tolerability of NBI-1117568, the company's ...
BioPharma Dive5d
Pfizer’s Bourla ‘cautiously optimistic’ on looming US pharma tariffs
The company’s CEO said he’s had “productive discussions” with Trump administration officials on a recently launched trade ...